Raltegravir in combination with other antiretroviral agents for the treatment of HIV infection

References

• Panel on Antiretroviral Guidelines for Adults and AdolescentsGuidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents Department of Health and Human Services12120091161 http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed 2009 December 20
   Google Scholar
• El-SadrWMLundgrenJD2NeatonJDCD4+ count-guided interruption of antiretroviral treatmentN Engl J Med2006355222283229617135583
   PubMed Web of Science ®Google Scholar
• KitahataMMGangeSJAbrahamAGEffect of early versus deferred antiretroviral therapy for HIV on survivalN Engl J Med2009360181815182619339714
   PubMed Web of Science ®Google Scholar
• HirschMSGunthardHFSchapiroJMAntiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panelClin Infect Dis200847226628518549313
   PubMed Web of Science ®Google Scholar
• CooperDASteigbigelRTGatellJMSubgroup and resistance analyses of raltegravir for resistant HIV-1 infectionN Engl J Med2008359435536518650513
   PubMed Web of Science ®Google Scholar
• ChirchLMMorrisonSSteigbigelRTTreatment of HIV infection with raltegravirExpert Opin Pharmacother20091071203121119385721
   PubMed Web of Science ®Google Scholar
• DelelisOCarayonKSaibADeprezEMouscadetJFIntegrase and integration: biochemical activities of HIV-1 integraseRetrovirology2008511419091057
   PubMed Web of Science ®Google Scholar
• EspesethASFelockPWolfeAHIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integraseProc Natl Acad Sci U S A20009721112441124911016953
   PubMed Web of Science ®Google Scholar
• IwamotoMWenningLAPetryASSafety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjectsClin Pharmacol Ther200883229329917713476
   PubMed Web of Science ®Google Scholar
• WenningLAHanleyWDBrainardDMEffect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravirAntimicrob Agents Chemother20095372852285619433563
   PubMed Web of Science ®Google Scholar
• HanleyWDWenningLAMoreauAEffect of tipranavir-ritonavir on pharmacokinetics of raltegravirAntimicrob Agents Chemother20095372752275519398643
   PubMed Web of Science ®Google Scholar
• IwamotoMWenningLAMistryGCAtazanavir modestly increases plasma levels of raltegravir in healthy subjectsClin Infect Dis200847113714018513146
   PubMed Web of Science ®Google Scholar
• IwamotoMWenningLANguyenBYEffects of omeprazole on plasma levels of raltegravirClin Infect Dis200948448949219143531
   PubMed Web of Science ®Google Scholar
• IwamotoMHanleyWDPetryASLack of a clinically important effect of moderate hepatic insufficiency and severe renal insufficiency on raltegravir pharmacokineticsAntimicrob Agents Chemother20095351747175219223645
   PubMed Web of Science ®Google Scholar
• MarkowitzMMorales-RamirezJONguyenBYAntiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individualsJ Acquir Immune Defic Syndr200643550951517133211
   PubMed Web of Science ®Google Scholar
• MarkowitzMNguyenBYGotuzzoERapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled studyJ Acquir Immune Defic Syndr200746212513317721395
   PubMed Web of Science ®Google Scholar
• MarkowitzMNguyenBYGotuzzoESustained Antiretroviral Effect of Raltegravir After 96 Weeks of Combination Therapy in Treatment-Naive Patients With HIV-1 InfectionJ Acquir Immune Defic Syndr200952335035619648823
   PubMed Web of Science ®Google Scholar
• LennoxJLDeJesusELazzarinASafety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trialLancet2009374969279680619647866
   PubMed Web of Science ®Google Scholar
• SedaghatARDinosoJBShenLDecay dynamics of HIV-1 depend on the inhibited stages of the viral life cycleProc Natl Acad Sci U S A2008105124832483718362342
   PubMed Web of Science ®Google Scholar
• GrinsztejnBNguyenBYKatlamaCSafety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trialLancet200736995691261126917434401
   PubMed Web of Science ®Google Scholar
• SteigbigelRTCooperDAKumarPNRaltegravir with optimized background therapy for resistant HIV-1 infectionN Engl J Med2008359433935418650512
   PubMed Web of Science ®Google Scholar
• SteigbigelRCooperDAEronJE96-week Results from BENCHMRK 1&2, Phase III Studies of Raltegravir in Patients failing Antiretroviral Therapy with Triple-Class Resistant HIVConference on Retroviruses and Opportunistic InfectionsMontreal, Canada2009
   Google Scholar
• EronJNguyenBYSteigbigelRTAIDS-Defining Conditions in the BENCHMRK 1 and 2 trials: 48 week analysis48th Annual ICAAC/IDSA 46th Annual MeetingWashington, DC2008
   Google Scholar
• MillerMDanovichRFransenSAnalysis of resistance to the HIV-1 integrase inhibitor raltegravir: results from BENCHMRK 1 and 248th Annual ICAAC/IDSA 46th Annual MeetingWashington, DC2008
   Google Scholar
• FransenSGuptaSDanovichRLoss of raltegravir susceptibility of HIV-1 is conferred by multiple non-overlapping genetic pathwaysJ Virol20098322114401144619759152
   PubMed Web of Science ®Google Scholar
• ZugerAReport from the XVI International AIDS Conference. ACTG 5142 compares class-sparing regimens in treatment-naive patientsAIDS Clin Care200618119817183744
   PubMedGoogle Scholar
• RipamontiDMaggioloFBombanaEEfficacy, safety, and tolerability of dual therapy with raltegravir and atazanavir in antiretroviral experienced patients5th International AIDS Society Conference on HIV Pathogenesis, Treatment and PreventionCape Town, South Africa2009
   Google Scholar
• DeCastroNBraunJCharreauISwitch from enfuvirtide to raltegravir in highly treatment-experienced HIV-1 infected patients: a randomized open-label non-inferiority trial, EASIER – ANRS138Program and Abstracts of the 16th Conference on Retroviruses and Opportunistic InfectionsMontreal, Canada2009
   Google Scholar
• EronJAndradeJZajdenbergRSwitching from stable lopinavir/ritonavir-based to raltegravir-based combination ART resulted in a superior lipid profile at week 12 but did not demonstrate non-inferior virologic efficacy at week 24Program and Abstracts of the 16th Conference on Retroviruses and Opportunistic InfectionsMontreal, Canada2009
   Google Scholar
• RheeSYHorbergMFollansbeeSVirologic response to raltegravir salvage and maintenance therapy47th IDSA Annual MeetingPhiladelphia, PA2009
   Google Scholar
• YazdanpanahYFagardCDescampsDHigh rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS TRIO trialClin Inf Dis200949914411449
   PubMed Web of Science ®Google Scholar
• CooperDASteigbigelRTLennoxJReview of cancer incidence in raltegravir clinical trials16th Conference on Retroviruses and Opportunistic InfectionsMontreal, Canada2009
   Google Scholar